首页> 美国卫生研究院文献>Therapeutics and Clinical Risk Management >Tapentadol extended release in the management of peripheral diabetic neuropathic pain
【2h】

Tapentadol extended release in the management of peripheral diabetic neuropathic pain

机译:他喷他多缓释治疗周围型糖尿病性神经性疼痛

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.
机译:他喷他多是一种μ阿片类激动剂和去甲肾上腺素再摄取抑制剂,已被发现可有效治疗多种慢性疼痛,包括背痛,与癌症有关的疼痛和关节炎性疼痛。还发现它比传统的基于阿片样物质的疗法具有更少的胃肠道副作用。最近,他喷他多缓释已被证明可有效治疗糖尿病性神经病变,这是一种经常使人衰弱的疾病,影响了大约三分之一的糖尿病患者。这篇综述着重于他喷他多的作用机理及其临床疗效,特别是在疼痛性糖尿病性神经病方面,重点介绍了最新的基础和临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号